Document   

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 

Date of Report (Date of earliest event reported): February 5, 2018

BRISTOL-MYERS SQUIBB COMPANY 

(Exact Name of Registrant as Specified in its Charter) 

[DATA_TABLE_REMOVED]

345 Park Avenue 

New York, NY 10154 

(Address of Principal Executive Office) 

Registrant’s telephone number, including area code: (212) 546-4000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Item 2.02. Results of Operations and Financial Condition.

On February 5, 2018, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the fourth quarter and twelve months of 2017. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com. 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. 

99.1Press release of Bristol-Myers Squibb Company dated February 5, 2018.

99.2Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

[DATA_TABLE_REMOVED]

EXHIBIT INDEX 

[DATA_TABLE_REMOVED]